INTERNATIONAL FLAVORS & FRAGRANCES INC
INTERNATIONAL FLAVORS & FRAGRANCES INC (IFF) Stock News
The latest IFF headlines and market coverage — 4 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights
A class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims the preclinical data was based on improper comparisons and lacked reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price declined approximately 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.
- GlobeNewswire Inc.·
Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
Firefly Neuroscience announced a nearly four-fold increase in TMS center customer clinical assessments using its FDA-cleared Evoke AI-powered EEG/ERP platform. The platform combines quantitative EEG and event-related potentials to help clinicians assess brain activity and tailor treatments for psychiatric and behavioral health conditions. The company continues to expand adoption among TMS centers while building its proprietary database of over 200,000 EEG/ERP brain scans.
- GlobeNewswire Inc.·
ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights
A class action lawsuit has been filed against Erasca, Inc. alleging the company made false statements about its ERAS-0015 drug candidate based on improper comparisons and lacking reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price plummeted 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.
- GlobeNewswire Inc.·
Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides
Firefly Neuroscience (NASDAQ: AIFF) and Next Health announced a strategic partnership to launch a precision cognitive health platform combining Firefly's FDA-cleared AI-powered EEG/ERP brain biomarker technology with personalized cognitive peptide protocols. The collaboration follows an FDA Advisory Committee's recommendation to ease compounding restrictions for six peptides, including Epitalon and Semax, which have shown potential neuroprotective and cognitive-supportive properties in scientific literature.